Prof Geoffrey Lindeman
Honorary (Professorial Fellow)
Department of Medicine
333 Scholarly works
20 Projects
HIGHLIGHTS
2026
Journal article
Abstract PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy
DOI: 10.1158/1557-3265.sabcs25-ps5-08-192026
Journal article
Abstract PS1-10-07: Progression free survival and exploratory endpoints from PALVEN: a phase 1b study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
DOI: 10.1158/1557-3265.sabcs25-ps1-10-072026
Journal article
Abstract PS5-07-29: Trial in progress: a phase 1 dose-escalation study evaluating BGB-21447 (BCL2 inhibitor) in combination with fulvestrant with and without BGB-43395 (CDK4 inhibitor) in patients with previously treated HR /HER2− metastatic breast cancer
DOI: 10.1158/1557-3265.sabcs25-ps5-07-292025
Research grants (ARC, NHMRC, MRFF)
Harnessing the Next Generation of Liquid Biopsy Assays for Clinical Translation in Breast Cancer
2023
Research grants (other domestic)
kConFab. The Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer
2023
Research grants (other domestic)
Targeting Novel Classes of Tumour Antigens in BRCA-deficient Breast Cancer to Improve Immunotherapy Responses and Overcome Resistance
2019
Journal article
A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2– positive metastatic breast cancer
DOI: 10.1158/2159-8290.CD-18-1151
RECENT SCHOLARLY WORKS
2026
Journal article
Integrating breast tumour homologous recombination deficiency status to aid germline BRCA1 and BRCA2 variant classification
DOI: 10.1016/j.ebiom.2026.1061992026
Journal article
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study
DOI: 10.1016/j.eururo.2026.01.0312025
Journal article
MCL‑1 safeguards activated hair follicle stem cells to enable adult hair regeneration
DOI: 10.1038/s41467-025-58150-52025
Journal article
Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer
DOI: 10.1182/bloodadvances.20250160632025
Journal article
617TiP Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR HER− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy
DOI: 10.1016/j.annonc.2025.08.10392025
Journal article
Abstract P51: MCL-1 safeguards activated hair follicle stem cells to enable adult hair regeneration
DOI: 10.1158/1538-7445.fcs2024-p512025
Journal article
Abstract P2-07-18: Results from PALVEN: A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL2-Positive Metastatic Breast Cancer
DOI: 10.1158/1557-3265.sabcs24-p2-07-18
RECENT PROJECTS
2026
Research grants (other domestic)
kConFab. The Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer